Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 8/20 | 0.74 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.74 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.74 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL229532 | 1.00 | CHRNB2 (0.74) | CHRNB2CHRNA4CHRNA7CYP2A6KDM4E | |
| SCHEMBL26181251 | 0.86 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| SCHEMBL26383447 | 0.86 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| SCHEMBL29634380 | 0.86 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| SCHEMBL229516 | 0.86 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| SCHEMBL11955257 | 0.86 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| SCHEMBL229515 | 0.86 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Hydrochloric Acid SCHEMBL29142854 | 0.84 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Glutarate SCHEMBL21240776 | 0.83 | CHRNB2 (0.72) | CHRNB2CHRNA4CHRNA7CYP2A6 | |
| Glutarate SCHEMBL22123428 | 0.83 | CHRNB2 (0.72) | CHRNB2CHRNA4CHRNA7CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237627-A1 | METHODS OF SYNTHESIZING ANATABINE | Rock Creek Pharmaceuticals, Inc. (US) | 2011-09-29 | — | — | US | claimed |
| EP-4208151-B1 | FREEZE DRIED LOW HYGROSCOPICITY ACTIVE POWDER COMPOSITIONS | PHILIP MORRIS PRODUCTS SA (CH) | 2024-07-10 | — | — | EP | disclosed |
| US-20230346696-A1 | SPRAY DRIED LOW HYGROSCOPICITY ACTIVE POWDER COMPOSITIONS | PHILIP MORRIS PRODUCTS S.A. (CH) | 2023-11-02 | — | — | US | disclosed |
| EP-3898607-B1 | 3-(1,2,3,6-TETRAHYDROPYRIDIN-2-YL)PYRIDINE GLUTARATE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF | PHILIP MORRIS PRODUCTS SA (CH) | 2023-10-18 | — | — | EP | disclosed |
| US-20230310315-A1 | LOW HYGROSCOPICITY ACTIVE POWDER COMPOSITIONS | PHILIP MORRIS PRODUCTS S.A. (CH) | 2023-10-05 | — | — | US | disclosed |
| US-20230301919-A1 | FREEZE DRIED LOW HYGROSCOPICITY ACTIVE POWDER COMPOSITIONS | PHILIP MORRIS PRODUCTS S.A. (CH) | 2023-09-28 | — | — | US | disclosed |
| US-20230233459-A1 | ANATABINE POWDER COMPOSITIONS | PHILIP MORRIS PRODUCTS S.A. (CH) | 2023-07-27 | — | — | US | disclosed |
| EP-4208152-A1 | LOW HYGROSCOPICITY ACTIVE POWDER COMPOSITIONS | Philip Morris Products S.A. (CH) | 2023-07-12 | — | — | EP | disclosed |
| EP-4208153-A1 | SPRAY DRIED LOW HYGROSCOPICITY ACTIVE POWDER COMPOSITIONS | Philip Morris Products S.A. (CH) | 2023-07-12 | — | — | EP | disclosed |
| EP-4208151-A1 | FREEZE DRIED LOW HYGROSCOPICITY ACTIVE POWDER COMPOSITIONS | Philip Morris Products S.A. (CH) | 2023-07-12 | — | — | EP | disclosed |
| EP-2549995-A2 | USE OF ANATABINE TO TREAT INFLAMMATION AND METHODS OF SYNTHESIZING ANATABINE | Rock Creek Pharmaceuticals, Inc. (US) | 2013-01-30 | — | — | EP | disclosed |
| WO-2012149295-A2 | METHODS OF ADMINISTERING ANATABINE TO TREAT AUTISM SPECTRUM DISORDERS AND SEIZURE DISORDERS | Rock Creek Pharmaceuticals, Inc. (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20120245202-A1 | METHODS AND PRODUCTS FOR TREATING INFLAMMATION | Rock Creek Pharmaceuticals, Inc. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120232115-A1 | PHARMACEUTICAL, DIETARY SUPPLEMENT, AND FOOD GRADE SALTS OF ANATABINE | Rock Creek Pharmaceuticals, Inc. (US) | 2012-09-13 | — | — | US | disclosed |
| US-8241680-B2 | Nutraceutical product containing anatabine and yerba maté | Rock Creek Pharmaceuticals, Inc. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120196899-A1 | METHODS AND PRODUCTS FOR TREATING INFLAMMATION | Rock Creek Pharmaceuticals, Inc. (US) | 2012-08-02 | — | — | US | disclosed |
| US-8207346-B2 | Methods of synthesizing anatabine | Rock Creek Pharmaceuticals, Inc. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20120003341-A1 | Nutraceutical Product Containing Anatabine And Yerba Maté | Rock Creek Pharmaceuticals, Inc. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110237627-A1 | METHODS OF SYNTHESIZING ANATABINE | Rock Creek Pharmaceuticals, Inc. (US) | 2011-09-29 | — | — | US | disclosed |
| WO-2011119722-A2 | USE OF ANATABINE TO TREAT INFLAMMATION AND METHODS OF SYNTHESIZING ANATABINE | Rock Creek Pharmaceuticals, Inc. (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346696-A1 | SPRAY DRIED LOW HYGROSCOPICITY ACTIVE POWDER COMPOSITIONS | TREH, SORD, UGCG | CHRNB2 1063/4885CHRNA4 1174/4885CHRNA7 548/4885 |
| US-20120003341-A1 | Nutraceutical Product Containing Anatabine And Yerba Maté | MAOB, TACR2, SLC19A1 | CHRNB2 285/4885CHRNA4 439/4885CHRNA7 280/4885 |
| US-20120232115-A1 | PHARMACEUTICAL, DIETARY SUPPLEMENT, AND FOOD GRADE SALTS OF ANATABINE | ALKBH1, AADAT, DIMT1 | CHRNB2 1454/4885CHRNA4 2077/4885CHRNA7 2757/4885 |
| US-20120245202-A1 | METHODS AND PRODUCTS FOR TREATING INFLAMMATION | IL1B, IL1A, IL5 | CHRNB2 2786/4885CHRNA4 3263/4885CHRNA7 2255/4885 |
| US-20230301919-A1 | FREEZE DRIED LOW HYGROSCOPICITY ACTIVE POWDER COMPOSITIONS | TREH, UGCG, MGAM | CHRNB2 1615/4885CHRNA4 1572/4885CHRNA7 909/4885 |
| US-20110237627-A1 | METHODS OF SYNTHESIZING ANATABINE | ALKBH1, ALKBH2, NME2 | CHRNB2 1366/4885CHRNA4 1686/4885CHRNA7 2481/4885 |
| US-20120196899-A1 | METHODS AND PRODUCTS FOR TREATING INFLAMMATION | IL1B, IL6, TLR5 | CHRNB2 1140/4885CHRNA4 1605/4885CHRNA7 987/4885 |
| US-20230310315-A1 | LOW HYGROSCOPICITY ACTIVE POWDER COMPOSITIONS | ERG28, SORD, IPMK | CHRNB2 955/4885CHRNA4 1090/4885CHRNA7 787/4885 |
| US-20230233459-A1 | ANATABINE POWDER COMPOSITIONS | ADORA2A, FUT5, FUT6 | CHRNB2 810/4885CHRNA4 764/4885CHRNA7 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.